10-K/A: Benitec Biopharma Amends 10-K, Boosts Cash Reserves

Sentiment:

Annual Report Amendment 20 March 2026 4:03 PM

Benitec Biopharma Inc. filed an amended annual report for fiscal year 2025 to include auditor signatures and updated certifications, while reporting increased cash and continued operational losses.

Capital raiseClosed a private investment in public equity (PIPE) financing on April 22, 2024, generating $40.0 million in gross proceeds.Received an additional $72.8 million in cash during fiscal year 2025 from warrant exercises, warrant issuances, and common stock issuances.Entered into a Sales Agreement on October 11, 2024, with Leerink Partners LLC, allowing the company to offer and sell up to $75 million of common stock through an at-the-market (ATM) offering. No sales under this agreement through June 30, 2025.Completed a $18.8 million gross proceeds underwritten public offering on March 25, 2025, issuing common stock and pre-funded warrants.Concurrently completed an $11.7 million gross proceeds registered direct offering on March 25, 2025, issuing common stock.Total net proceeds from financing activities during fiscal year 2025 amounted to $70.5 million.

Worse than expectedNet loss increased to $37.9 million for FY2025 from $21.8 million for FY2024.Net cash used in operating activities increased to $23.6 million for FY2025 from $19.4 million for FY2024, indicating a higher cash burn rate.General and administrative expenses rose substantially to $23.4 million in FY2025 from $7.0 million in FY2024.Research and development expenses increased to $18.3 million in FY2025 from $15.6 million in FY2024.

Summary

The company filed an Amendment No. 1 (Form 10-K/A) to its Annual Report on Form 10-K for the fiscal year ended June 30, 2025, primarily to include the conformed signature of Baker Tilly US, LLP and new CEO/CFO certifications.
Restated prior unaudited interim financial statements for March 31, 2025, and December 31, 2024, to correct an immaterial error in share-based compensation expense calculation.
Net loss increased to $37.9 million for the fiscal year ended June 30, 2025, compared to $21.8 million for the prior fiscal year.
Cash and cash equivalents significantly increased to $97.7 million as of June 30, 2025, from $50.9 million as of June 30, 2024.
Net cash used in operating activities increased to $23.6 million for FY2025 from $19.4 million for FY2024.
General and administrative expenses rose sharply to $23.4 million in FY2025 from $7.0 million in FY2024.
The company raised substantial capital through various offerings and warrant exercises, totaling $70.5 million in net proceeds during fiscal year 2025.
Management estimates current cash and cash equivalents are sufficient to fund operations for at least the next twelve months from the report date (March 20, 2026).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the company successfully raised significant capital, substantially increasing its cash reserves and extending its operational runway, the underlying financial performance shows widening losses and increased cash burn, which are concerning trends for an early-stage biotech.

Positives

Cash and cash equivalents increased significantly to $97.7 million as of June 30, 2025, from $50.9 million as of June 30, 2024.
Successfully raised $70.5 million in net proceeds from financing activities during fiscal year 2025.
Management projects sufficient cash to fund operations for at least the next twelve months from the report date.
Net loss per share improved to $(1.05) for FY2025 from $(1.22) for FY2024, despite a higher net loss, due to increased shares outstanding.
A gain on extinguishment of liabilities of $764 thousand was recorded in FY2025.

Negatives

Net loss increased to $37.9 million for the fiscal year ended June 30, 2025, compared to $21.8 million for the prior fiscal year.
Net cash used in operating activities increased to $23.6 million for FY2025 from $19.4 million for FY2024, indicating higher cash burn.
General and administrative expenses rose substantially to $23.4 million in FY2025 from $7.0 million in FY2024.
Research and development expenses increased to $18.3 million in FY2025 from $15.6 million in FY2024.
The company continues to incur operating losses and has not established a source of revenue to cover operating costs.
A valuation allowance of $25.0 million was established against deferred tax assets due to uncertainty of realization.

Risks

Risks and uncertainties common to early-stage companies in the biotechnology industry.
Development by competitors of new technological innovations.
Challenges in protection of proprietary technology.
Dependence on key personnel.
Reliance on single-source vendors and collaborators.
Availability of raw materials.
Patentability of products and processes.
Clinical efficacy and safety of products under development.
Compliance with government regulations.
Need to obtain additional financing to fund operations.
Uncertainty regarding successful completion of research and development, obtaining/maintaining intellectual property protection, government regulatory approval, or commercial viability of products.
Utilization of Net Operating Loss (NOL) carryforwards may be subject to annual limitation due to Internal Revenue Code Section 382.

Future Outlook

Management estimates that current cash and cash equivalents will be sufficient to fund operations for at least the next twelve months from the report date of March 20, 2026. The company's ability to continue as a going concern is dependent on managing net loss, achieving profitability, and securing adequate future financing.

Management Comments

"Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report." (Dr. Jerel Banks, CEO)
"Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report." (Dr. Jerel Banks, CEO and Megan Boston, CFO)
"The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures... and internal control over financial reporting... and have designed such disclosure controls and procedures... to ensure that material information... is made known to us... and designed such internal control over financial reporting... to provide reasonable assurance regarding the reliability of financial reporting." (Dr. Jerel Banks, CEO and Megan Boston, CFO)

Industry Context

StockSavvy.ai notes that Benitec Biopharma's continued reliance on capital financing to cover operating costs is typical for early-stage biotechnology companies focused on novel genetic medicines. The significant increase in cash reserves, primarily from financing activities, provides a crucial runway for ongoing research and development in a highly competitive and capital-intensive sector. However, the escalating R&D and G&A expenses, coupled with increasing net losses, highlight the inherent challenges and long development cycles in bringing genetic therapies to market, a common theme across the biotech industry.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Class I Director	NA	Kishen Mehta	2024-06-26	Appointed to the Board pursuant to a Board Designation Agreement with Suvretta Capital, a significant investor.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Authorized Shares Increase (Common Stock)	Stockholders approved an amendment to increase the total number of authorized shares of common stock from 10,000,000 to 40,000,000.	2021-12-17	Facilitates future equity raises and employee incentive plans, but also enables potential dilution.
Authorized Shares Increase (Common Stock)	Stockholders approved an amendment to increase the total number of authorized shares of common stock from 40,000,000 to 160,000,000.	2022-12-09	Further expands capacity for equity financing and stock-based compensation, increasing potential for dilution.
Reverse Stock Split	Effected a 1-for-17 reverse stock split.	2023-07-26	Aimed to increase per-share price, potentially to maintain Nasdaq listing compliance, but reduces the number of outstanding shares.
Authorized Shares Increase (Preferred Stock)	Stockholders approved an amendment to authorize the issuance of 5,000,000 shares of preferred stock, par value $0.0001.	2024-12-06	Provides flexibility for future financing with potentially different rights and preferences, which could impact common stockholders.
Equity Incentive Plan Amendment	Stockholders approved an amendment to the 2020 Equity and Incentive Compensation Plan, increasing the number of shares reserved to 8,204,537.	2024-08-29	Expands the pool for employee and director equity awards, aligning incentives but also contributing to potential dilution.
Warrant Beneficial Ownership Limitation Waiver	Stockholders approved the exercise of certain existing warrants to waive the 19.99% beneficial ownership limitation, with Suvretta Capital subsequently waiving to a 49.9% limitation.	2024-08-29	Allows large institutional investors to exercise more warrants without triggering beneficial ownership restrictions, potentially increasing their stake and influence.

Legal Proceedings

Not a party to any material legal proceedings, nor aware of any material pending or threatened litigation.

Related Party Transactions

Entities affiliated with Suvretta, Franklin Resources, and Janus Henderson Group plc (all beneficial owners of more than 5% of common stock) participated in the August 11, 2023 public offering on the same terms as other investors.
Kevin Buchi (director) purchased 51,813 shares of common stock for approximately $99,999 in the August 11, 2023 offering.
Megan Boston (CFO and director) purchased 25,907 shares of common stock for approximately $50,000 in the August 11, 2023 offering.
Entities affiliated with Suvretta Capital ($16,750,004) and Franklin Resources, Inc. ($1,000,003) (both >5% stockholders) participated in the April 22, 2024 private placement.
Nemean Asset Management, Adage Capital Partners, HBM Healthcare Investments, Nantahala Capital Management, and Special Situations Fund became beneficial owners of more than 5% of outstanding common stock following the April 2024 private placement.
Entered into a Voting Commitment Agreement with purchasers in the April 2024 private placement, obligating the company to seek stockholder approval for warrant exercises to waive beneficial ownership limitations.
Entered into a Board Designation Side Letter with Suvretta Capital at the closing of the April 2024 private placement, leading to the appointment of Kishen Mehta to the Board on June 26, 2024.
Suvretta Capital waived the 19.99% beneficial ownership limitation on September 26, 2024, agreeing to a 49.9% limitation.
Entities affiliated with Suvretta Capital participated in the March 25, 2025 registered direct offering.

Stakeholder Impact

Shareholders: Significant dilution from multiple capital raises and warrant exercises, but also increased liquidity and extended operational runway. Continued net losses pose a risk to long-term value.
Employees: Share-based compensation plans are in place, aligning incentives. The restatement of share-based compensation expense indicates a correction in how their equity awards are accounted for.
Creditors: Improved cash position reduces immediate liquidity concerns, potentially enhancing creditworthiness.
Customers/Patients: Continued R&D investment in genetic medicines suggests potential for future therapeutic products.
Management: Certifications confirm responsibility for financial reporting and internal controls. Participation in offerings by CEO/CFO shows alignment.

Next Steps

Continue development of novel genetic medicines using the Silence and Replace DNA-directed RNA interference platform.
Manage net loss and work towards profitability.
Obtain adequate additional financing as needed.
Evaluate the impact of ASU 2023-09 (Income Tax Disclosures) and ASU 2024-03 (Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures) on future financial statements.
Register shares for resale no later than 60 days following the closing of the registered direct offering (March 25, 2025).

Key Dates

Date	Description
1995	Benitec Biopharma Limited (BBL) incorporated under Australian laws.
1997	BBL listed on the Australian Securities Exchange (ASX).
2019-11-22	Benitec Biopharma Inc. formed under Delaware laws.
2019-12-06	Investors were issued four Purchase Warrants, exercisable until December 6, 2024.
2020-04-15	BBL delisted from ASX.
2020-04-22	Company issued 2,201 shares of common stock in connection with a cashless exercise of Purchase Warrants.
2020-08-14	BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited.
2020-12-09	Stockholders approved the 2020 Equity and Incentive Compensation Plan.
2021-12-08	Stockholders approved an amendment to the 2020 Plan, increasing reserved shares.
2021-12-17	Amendment to Certificate of Incorporation effective, increasing authorized common stock to 40,000,000 shares.
2022-09-15	Closed an underwritten public offering, issuing common stock, pre-funded warrants, and Series 2 warrants.
2022-10-17	Investors exercised 117,939 pre-funded warrants.
2022-10-27	Investors exercised 9,804 pre-funded warrants.
2022-12-07	Stockholders approved an amendment to the Certificate of Incorporation, increasing authorized common stock to 160,000,000 shares.
2022-12-09	Amendment to Certificate of Incorporation effective, increasing authorized common stock to 160,000,000 shares; Series 2 warrants became exercisable.
2023-07-26	Effected a 1-for-17 reverse stock split.
2023-08-11	Closed an underwritten public offering (2023 Offering) of common stock, pre-funded warrants, and common warrants; Series 2 Warrants exercise price reset to $1.9299.
2023-10-17	An investor exercised 25,000 pre-funded warrants.
2023-11-24	An investor exercised 20,000 Series 2 warrants.
2023-12-06	Stockholders approved an amendment to the 2020 Plan, increasing reserved shares to 1,204,537.
2023-12-31	Aggregate market value of common equity held by non-affiliates was approximately $152,964,292.
2024-03-15	Investors exercised 105,888 pre-funded warrants.
2024-03-18	Investors exercised 26,472 pre-funded warrants.
2024-04-10	Investors exercised 25,000 Series 2 warrants.
2024-04-19	Investors exercised 25,000 Series 2 warrants.
2024-04-22	Closed a private investment in public equity (PIPE) financing.
2024-04-23	Investors exercised 27,500 common warrants.
2024-04-26	Investors exercised 350,000 pre-funded warrants.
2024-04-28	Investors exercised 438,000 pre-funded warrants.
2024-05-08	Investors exercised 697,475 common warrants.
2024-05-16	Investors exercised 7,947 pre-funded warrants.
2024-05-21	Investors exercised 13,212 common warrants.
2024-06-26	Kishen Mehta appointed to the Board as a Class I director.
2024-06-27	California Governor signed Senate Bill 167 (SB 167) limiting NOL and business credit use.
2024-07-01	The Prior Plan and all options granted thereunder expired.
2024-07-25	An investor exercised 269,609 Series 2 warrants.
2024-08-29	Stockholders approved an amendment to the 2020 Plan, increasing reserved shares to 8,204,537; Stockholders approved the exercise of certain existing warrants to waive beneficial ownership limitation.
2024-09-12	An investor exercised 200,000 pre-funded warrants.
2024-09-17	26,250,469 shares of common stock outstanding.
2024-09-22	Original Annual Report on Form 10-K for fiscal year ended June 30, 2025, filed with the SEC.
2024-09-26	Investors exercised 1,368,180 pre-funded warrants and 5,181,347 common warrants; an investor exercised 588,236 Series 2 warrants; Suvretta Capital waived 19.99% beneficial ownership limitation, now subject to 49.9%.
2024-09-27	An investor exercised 200,274 pre-funded warrants on a cashless basis.
2024-10-11	Entered into a Sales Agreement with Leerink Partners LLC for an at-the-market offering of up to $75 million.
2024-10-15	An investor exercised 425,000 pre-funded warrants; investors exercised 1,496,214 common warrants.
2024-10-17	Investors exercised 308,803 common warrants.
2024-10-18	Investors exercised 950,000 common warrants.
2024-10-29	Investors exercised 1,554,404 common warrants; an investor exercised 588,239 Series 2 warrants.
2024-12-06	Stockholders approved an amendment to authorize 5,000,000 shares of preferred stock.
2024-12-09	Executive Options granted on this date vest in sixteen substantially equal quarterly installments.
2024-12-12	An investor exercised 181,129 pre-funded warrants on a cashless basis.
2024-12-18	Investors exercised 53,921 Series 2 warrants.
2024-12-27	Executive Options granted on this date vest in sixteen substantially equal quarterly installments.
2025-02-01	Entered into a new operating lease for office space with an initial expiration date in 2026.
2025-02-24	Entered into an amendment to an existing lease to extend the lease expiration date to 2027.
2025-02-25	An investor exercised 51,813 common warrants.
2025-03-20	Date of filing of this Form 10-K/A and new certifications from CEO and CFO.
2025-03-25	Entered into an underwriting agreement for the 2025 Underwritten Offering and a Securities Purchase Agreement for a registered direct offering.
2025-04-11	An investor exercised 53,922 Series 2 warrants.
2025-05-20	An investor exercised 650,259 common warrants.
2025-06-30	Fiscal year end for the reported financial statements.
2025-07	U.S. government enacted the One Big Beautiful Bill Act of 2025 (OBBB) tax reform legislation.

Recommendation

hold

While Benitec Biopharma has significantly bolstered its cash reserves through recent capital raises, providing a crucial operational runway for at least the next twelve months, the substantial increase in net losses and cash used in operations for fiscal year 2025 is a significant concern. The company remains in an early-stage development phase with no revenue, making it highly dependent on continuous financing. The successful capital raises and warrant exercises demonstrate investor support, but the escalating expenses and widening losses suggest that the path to profitability is still distant and capital-intensive. Given the high-risk nature of early-stage biotech and the mixed financial signals, a 'hold' recommendation is appropriate, advising investors to monitor progress in clinical development and expense management closely before making further commitments.

Keywords

genetic medicines, RNAi, gene therapy, biotechnology, SEC filing, 10-K/A, financial results, capital raise, warrants, stock options, liquidity, research and development, corporate governance, Nasdaq, BNTC

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.